Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 41, Issue 5 SUPPL., 1996, Pages 428-433

  Cullins, Vanessa E ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Family Planning Services   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

breast cancer; candidiasis, vulvovaginal; depo medroxyprogesterone acetate; DMPA; dysmenorrhea; endometrial cancer; endometriosis; iron deficiency anemia; ovarian cancer; pelvic inflammatory disease; sickle cell disease

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

DRUG EFFECT; ENDOMETRIUM CANCER; HORMONAL CONTRACEPTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; OVULATION INHIBITION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, IRON-DEFICIENCY; ANEMIA, SICKLE CELL; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; PELVIC INFLAMMATORY DISEASE;

EID: 0029995769     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Kaunitz AM: Injectable contraception. Clin Obstet Gynecol 1989;32:356-368
2. Kaunitz AM: Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994;170:1543-1549
3. Depo-Provera. Physicians Desk Reference. Forty-ninth edition. Montvale, NJ, Medical Economics, 1995, pp 2543-2546
4. U.S. Preventive Services Task Force: Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. Baltimore, Williams & Wilkins, 1989
5. Grimes DA: Graduate education: Introducing evidence-based medicine into a department of obstetrics and gynecology. Obstet Gynecol 1995;86:451-457
6. Fotherby K, Koetsawang S, Mathrubutham M: A pharmacokinetic study of different doses of Depo-Provera. Contraception 1980;22:527-536
7. Bassol S, Garza-Flores J, Cravioto MC, et al: Ovarian function following a single administration of depot medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril 1984; 42:216-222
8. Dawood MY: Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med 1988;84:23-29
9. Dawood MY: Current concepts in the etiology and treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand (suppl) 1986;138:7-10
10. Shapiro SS: Flurbiprofen for the treatment of primary dysmenorrhea. Am J Med 1986;80:71-75
11. World Health Organization, Special Programme of Research, Development and Research Training in Reproduction: A multicentred phase III comparative clinical trial of depot medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraception efficacy and side effects. Contraception 1986;34:223-235
12. World Health Organization, Special Programme of Research, Development and Research Training in Reproduction: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone enanthate and medroxyprogesterone acetate: 1. Use-effectiveness. Contraception 1977;15:513-533
13. World Health Organization, Special Programme of Research, Development and Research Training in Reproduction: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone enanthate and medroxyprogesterone acetate: 2. Bleeding patterns and side effects. Contraception 1978;17:395-406
14. World Health Organization, Special Programme of Research, Development and Research Training in Reproduction: Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot medroxyprogesterone acetate: Final Report. Contraception 1983;28:1-20
15. Schwallie PC, Assenzo JR: Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-339
16. Frazer IS, Dennerstein GJ: Depo-Provera use in an Australian metropolitan practice. Med J Aust 1994;160:553-556
17. De Ceulaer K, Hayes R, Gruber C, et al: Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982;2:229-231
18. Jacobs SA, Blumenthal NJ: Endometrial resection follow up: Late onset of pain and the effect of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1994;101:605-609
19. Derman SG, Rehnstrom J, Neuwirth RS: The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991;77:591-594
20. Kistner RW: The treatment of endometriosis by inducing pseudopregnancy with ovarian hormones: A report of fiftyeight cases. Fertil Steril 1959;10:539-556
21. Gunning JE, Moyer D: The effect of medroxyprogesterone acetate on endometriosis in the human female. Fertil Steril 1967;18:759-774
22. Schlesselman JJ: Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991;43:557-579
23. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Depot medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186-190
24. Depot medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting. Bull WHO 1993;71: 669-676
25. Ferenczy A, Gelfand M: The biologic significance of cytologie atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131
26. Gal D: Hormonal therapy for lesions of the endometrium. Semin Oncol 1986;13:33-36
27. Kurman RJ, Kaminski PF, Morris HJ: The behavior of endometrial hyperplasia: A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-412
28. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Depot medroxyprogesterone acetate and risk of epithelial ovarian cancer. Int J Cancer 1991;49:191-195
29. Gray RH: Reduced risk of pelvic inflammatory disease with injectable contraceptives (lett). Lancet 1985;1:1046
30. WHO Task Force of Intrauterine Devices: PID associated with fertility-regulating agents. Contraception 1984;30:1-21
31. Isaacs WA, Hayhoe FGJ: Steroid hormones in sickle-cell disease. Nature 1967;215:1139-1142
32. Backstrom T: Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976;54:321-347
33. Mattson RH, Cramer JA, Caldwell BV, et al: Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 1984;34:1255-1258
34. Mattson RH, Cramer JA: Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia 1985;26:S40-S51
35. Blackham A, Spencer PSJ: Response of female mice to anti-convulsants after pretreatment with sex steroids (lett). J Pharm Pharmacol 1970;22:304-305
36. Zimmerman AW, Holden KR, Reiter EO, et al: Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J Pediatr 1973;83:959-963
37. Machida H: Influence of progesterone on arterial blood and CSF and acid-base balance in women. J Appl Physiol 1981;51:1433-1436
38. Strohl KP, Hensley MJ, Saunders NA, et al: Progesterone administration and progressive sleep apneas. JAMA 1981;245:1230-1232
39. Orr WC, Imes NK, Martin RJ: Progesterone therapy in obese patients with sleep apnea. Arch Intern Med 1979;139:109-111
40. Collop NA: Medroxyprogesterone acetate and ethanol-induced exacerbation of obstructive sleep apnea. Chest 1994; 106:792-799
41. Dolly FR, Block AJ: Medroxyprogesterone acetate and COPD: Effect of breathing and oxygenation in sleeping and awake patients. Chest 1983;84:394-398
42. Toppozada M, Onsy FA, Fares E, et al: The protective influence of progesterone-only contraception against vaginal moniliasis. Contraception 1979;20:99-103
43. Dennerstein GJ: Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 1986;31:801-803
44. Beyond pharmacology: Oophorectomy advocated as cure for severe PMS. Ob/Gyn News. September 1, 1995
45. Martorano JT, Ahlgrimm M, Myers D: Differentiating between natural progesterone and synthetic progestogens: Clinical implications for premenstrual syndrome management. Compr Ther 1993;19:96-98
46. Albrecht BH, Schiff I, Tulchinsky D, et al: Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631-635
47. Morrison JC, Martin DC, Blair RA, et al: The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104
48. Bullock JL, Massey FM, Gambrell RD Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168
49. Lobo RA, McCormick W, Singer F, et al: Depomedroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1-5
50. Kaplan SA, Ling SM, Irani NG: Idiopathic isosexual precocity: Therapy with medroxyprogesterone. Am J Dis Child 1968; 116:591-598
51. Rifkind AB, Kulin HE, Cargille CM, et al: Suppression of urinary excretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by medroxyprogesterone acetate. J Clin Endocrinol Metab 1969;29:506-513
52. Haller DG, Blick JH: Progestational agents in advanced breast cancer: An overview (suppl). Semin Oncol 1986;13:2-8
53. Sikic BI, Scudder SA, Ballon SC, et al: High-dose megestrol acetate therapy of ovarian carcinoma: A phase II study by the Northern California Oncology Group. Semin Oncol (suppl) 1986;13:26-32
54. Bloom HJG: Medroxyprotesterone acetate (Provera) in the treatment of metastatic renal cancer, (submitted for publication)
55. Samuels ML, Sullivan P, Howe CD: Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma). Cancer 1968;22:525-532
56. Pizzocaro G, Piva L, DiFronzo G, et al: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-Year results of a prospective randomized study. J Urol 1987;138:1379-1381
57. Hrushesky WJ, Murphy GP: Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;9:277-288